title: Data on the safety of psoriasis therapies.
abstract: Safety remains paramount to the clinical utility of a therapy. Evaluation of safety is an ongoing process that does not end when a therapy becomes commercially available. This article reviews recent data pertaining to the safety profile of two therapeutic classes widely used in the treatment of psoriasis: inhibitors of tumor necrosis factor-α and agents that target interleukin-12/23.
authors.affiliation: Clinical Professor of Dermatology, Saint Louis University Central Dermatology, St Louis, MO.
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
mesh_terms: D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors*; D053759:Interleukin-23 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D003879:Dermatologic Agents; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12
keywords: Janus kinase inhibitor; Tumor necrosis factor; interleukin-12; interleukin-23; psoriasis; rheumatoid arthritis